On this week's Stansberry Investor Hour, Dan and Corey welcome their colleague John Engel to the podcast. John is the lead equity analyst on the Stansberry Innovations Report newsletter, where he finds companies that are revolutionizing their respective industries with cutting-edge technology. He also works on Prosperity Investor, a newsletter that focuses on opportunities in the health care sector.
John kicks off the show by detailing the new Biosecure Act that's currently moving through Congress. Its purpose is to limit China's access to U.S. biological information. As he explains, this legislation is going to disrupt the industry, hurt biotech companies, and possibly even bankrupt the smaller players. But, conversely, it's going to allow other contract development and management organizations to replace Chinese ones, creating massive opportunities for investors. John also shares how he got his start in the biotech field at a fermentation lab and as a molecular biologist before shifting to the world of finance.
Next, John talks about the pandemic, vaccines, and the current bear market in biotech. He mentions one big story in biotech that he believes isn't getting enough attention - bispecific antibodies. This development allows one drug to hit two targets, so patients no longer have to receive two different drugs for treatment. This leads to a conversation about gene editing, personalized medicine, and rare diseases.
Finally, John delves into AI, Nvidia, and the "hype cycle" surrounding the technology. He points out that companies are desperate to use AI to their advantage, but for many of them, there's no use for it in their business. Plus, John discusses "advanced general intelligence," which involves systems that can reason like human beings.
0:00 Biosecure Act, China, John's background
20:13 Bispecific antibodies, gene editing, rare diseases
40:24 All things AI